ClinicalTrials.gov
public full text
Public Domain
Investigating the Efficacy and Safety ICATIBANT For The Treatment of Patients With SARS-CoV-2 (COVID-19) Infection
To study the efficacy and safety of icatibant in adult patients admitted to hospitalization units for pneumonia caused by COVID-19, without mechanical ventilation, 10±1 days after starting treatment or discharge from hospital if this occurs before 10 days.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Cross-sectional Study of COVID-19 Infection in Hospital Health Personnel#832050
- Convalescent Plasma and Placebo for the Treatment of COVID-19 Severe Pneumonia#1210877
- COVID-19: Pediatric Research Immune Network on SARS-CoV-2 and MIS-C#826416
- A Trial of Remdesivir in Adults With Mild and Moderate COVID-19#842178
- Sarilumab COVID-19#895488
Record · ID 1365235
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive